198 related articles for article (PubMed ID: 37793875)
1. [Current state of treatment for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2023; 64(9):988-997. PubMed ID: 37793875
[TBL] [Abstract][Full Text] [Related]
2. [Updated treatment strategies for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2022; 63(6):660-666. PubMed ID: 36184521
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
4. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
7. Risk stratifying MDS in the time of precision medicine.
Cazzola M
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Stone R; Sekeres M; Garcia-Manero G; Lyons RM
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
[TBL] [Abstract][Full Text] [Related]
9. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
10. [Myelodysplastic syndromes (MDS)].
Kizaki M
Nihon Rinsho; 2014 Jun; 72(6):1079-86. PubMed ID: 25016808
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
[TBL] [Abstract][Full Text] [Related]
13. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
14. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY
Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590
[TBL] [Abstract][Full Text] [Related]
15. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
[TBL] [Abstract][Full Text] [Related]
17. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
18. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]